Background Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an
intravenous blocker of the adenosine diphosphate receptor P2Y12. This agent might have a …

Background The intensity of antiplatelet therapy during percutaneous coronary intervention
(PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a …

Background Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP)
receptor antagonist, might reduce ischemic events during percutaneous coronary …

BACKGROUND: Despite robust efficacy in the reduction of ischemic events in patients who
require percutaneous coronary intervention (PCI), current P2Y12 inhibitors have limitations …

Background Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that
was tested for percutaneous coronary intervention (PCI) in three large, double-blind …

Cangrelor is an intravenous antagonist of the P2Y 12 receptor characterized by rapid,
potent, predictable, and reversible platelet inhibition. However, cangrelor was not superior to …

BACKGROUND: There is a clinical need for an intravenous P2Y12 inhibitor in patients with
acute coronary syndromes (ACS) for patients who are unable to take oral medications or …

In patients with acute coronary syndromes and undergoing percutaneous coronary
intervention, numerous large-scale clinical trials have shown that adjunctive treatment with …

Cangrelor is the only currently available intravenous platelet P2Y12 receptor inhibitor. It is
characterized by potent, predictable, and rapidly reversible antiplatelet effects. Cangrelor …

Background: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are
delayed in patients with ST-segment–elevation myocardial infarction undergoing primary …